Overview

* Biofrontera Q3 revenue of $7 mln missed analyst expectations due to advanced purchases in 2024

* Adjusted EBITDA for Q3 was negative $6 mln, missing analyst estimates

* Company completed purchase of US Ameluz and RhodoLED assets, reducing royalty payments

Outlook

* Company anticipates substantial 4Q25 and annual revenue growth due to price normalization

* Biofrontera expects enhanced margins from new Ameluz and RhodoLED royalty structure

* Company sees potential FDA approval for Ameluz in new indications, expanding market opportunities

Result Drivers

* ADVANCED PURCHASES - Q3 revenue decline attributed to advanced purchases in 2024 ahead of price increase

* ASSET ACQUISITION - Purchase of Ameluz and RhodoLED assets expected to enhance margins and profitability

* COMMERCIAL STRATEGY - Revamped sales strategy and customer segmentation proving effective

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $7 mln $9 mln

Revenue (2

Analysts

)

Q3 Net -$6.60

Income mln

Q3 Miss -$6 mln -$2.60

Adjusted mln (1

EBITDA Analyst)

Q3 $13.30

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Biofrontera Inc ( BFRI ) is $6.00, about 83.8% above its November 12 closing price of $0.97

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)